Rhabdomyosarcoma

Researchers are testing daraxonrasib, an experimental pill that blocks RAS proteins, in children with solid tumors that have come back or stopped responding to treatment. The tumors include neuroblastoma and rhabdomyosarcoma, and all carry RAS mutations. The trial has two parts: …

This Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-…

This early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…

This study tests whether a green dye called indocyanine green (ICG) can help surgeons find sentinel lymph nodes—the first nodes where cancer might spread—in children with solid tumors. Ten children under 18 will get the dye injected during surgery, and doctors will check if it li…

This study tests whether light therapy (photobiomodulation) can prevent mouth sores in children receiving chemotherapy. Fifty children aged 0-30 will receive daily light treatments during hospital stays and at home. Researchers will check if the therapy is easy to use and accepta…

This study is testing a mobile app called my.naviGATE for teens and young adults (ages 15-24) who have finished cancer treatment. The app provides personalized education, peer support, and tracks how patients are doing. Researchers want to see if the app helps patients feel more …